Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up – Here’s Why

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares gapped up prior to trading on Monday . The stock had previously closed at $15.76, but opened at $17.51. Adaptive Biotechnologies shares last traded at $17.7420, with a volume of 718,687 shares traded.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Guggenheim began coverage on Adaptive Biotechnologies in a research note on Tuesday, September 30th. They issued a “buy” rating and a $20.00 target price on the stock. Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price objective on the stock. JPMorgan Chase & Co. increased their target price on shares of Adaptive Biotechnologies from $17.00 to $20.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Wall Street Zen upgraded shares of Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, October 8th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Adaptive Biotechnologies currently has an average rating of “Moderate Buy” and an average price target of $17.11.

Adaptive Biotechnologies Trading Up 15.5%

The company has a market cap of $2.78 billion, a PE ratio of -33.61 and a beta of 2.18. The firm’s 50-day simple moving average is $16.45 and its two-hundred day simple moving average is $14.33.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The firm had revenue of $93.97 million for the quarter, compared to analyst estimates of $58.76 million. During the same period in the previous year, the company earned ($0.22) earnings per share. The business’s quarterly revenue was up 102.4% compared to the same quarter last year. As a group, analysts predict that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Insider Transactions at Adaptive Biotechnologies

In related news, insider Harlan S. Robins sold 27,212 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $18.61, for a total value of $506,415.32. Following the transaction, the insider owned 1,242,312 shares in the company, valued at approximately $23,119,426.32. This represents a 2.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Sharon Benzeno sold 308,477 shares of the firm’s stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $16.91, for a total transaction of $5,216,346.07. Following the transaction, the insider directly owned 296,791 shares of the company’s stock, valued at $5,018,735.81. This represents a 50.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 1,358,650 shares of company stock valued at $23,122,398. 6.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC boosted its holdings in Adaptive Biotechnologies by 46.7% in the fourth quarter. SG Americas Securities LLC now owns 99,935 shares of the company’s stock valued at $1,623,000 after purchasing an additional 31,822 shares during the last quarter. Diversified Trust Co. lifted its holdings in shares of Adaptive Biotechnologies by 5.6% in the 4th quarter. Diversified Trust Co. now owns 42,200 shares of the company’s stock valued at $685,000 after buying an additional 2,224 shares during the period. Avior Wealth Management LLC acquired a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at about $187,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Adaptive Biotechnologies in the third quarter worth about $238,000. Finally, Harvest Investment Services LLC grew its holdings in Adaptive Biotechnologies by 104.7% during the third quarter. Harvest Investment Services LLC now owns 344,512 shares of the company’s stock worth $5,154,000 after acquiring an additional 176,235 shares during the period. Hedge funds and other institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.